Our expert, award-winning staff selects the products we cover and rigorously researches and tests our top picks. If you buy through our links, we may get a commission. Reviews ethics statement ...

On Friday, Evercore ISI initiated coverage on Edgewise Therapeutics (NASDAQ:EWTX) shares, a biopharmaceutical company, with an Outperform rating and a price target of ...

Nine million households need to submit energy meter readings by midnight tonight to avoid overpaying on their bills, findings have warned. Comparison website Uswitch says that Britons risk ...

Edgewise Therapeutics (NASDAQ:EWTX) is building itself up as a good long-term biotech to hang onto. Especially, when you consider that it was able to report positive results from its phase 2 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Householders have been urged to submit energy meter readings by the end of the year or risk overpaying their bills. Ofgem announced in November that the energy price cap will increase from £1,717 ...

To avoid being overcharged, you should submit a meter reading before the price cap increases. Doing so guarantees that all of the energy you use before January 1 is charged at the lower rate.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) experienced a notable 21% increase in premarket trading today following the announcement of successful results from its Phase 2 CANYON trial. The ...

Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy. The stock rose 5.4% to $29.11 ...